Modeling the trajectory of tau deposition in autosomal‐dominant Alzheimer's disease using the high‐affinity tau tracer [18F]MK6240: Neuroimaging / Optimal neuroimaging measures for tracking disease progression. (7th December 2020)

• Record Type: Journal Article
• Authors: Lussier, Firoza Z; Therriault, Joseph; Pascoal, Tharick A.; Benedet, Andréa Lessa; Tissot, Cécile; Savard, Mélissa; Kang, Min Su; Mathotaarachchi, Sulantha; Stevenson, Jenna; Robb, Laura; Rosa‐Neto, Pedro
• Is Part Of: Alzheimer's & dementia. Volume 16(2020)Supplement 4
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-07
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.045212
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Evidence suggests that Alzheimer's disease (AD) pathology may appear many years prior to the manifestation of clinical symptoms. While autosomal‐dominant AD (ADAD) only accounts for approximately 1% of AD cases, evidence shows it has similar pathophysiological features to sporadic AD. ADAD provides a unique and powerful means to model the pathophysiological cascade of events leading to clinical dementia during this asymptomatic stage, due to the complete penetrance of ADAD genetic mutations and the consistency of age at symptom onset between generations. Objective: To investigate tau deposition in vivo across the course of ADAD in mutation carriers (MC) and noncarriers (NC) using the high‐affinity tau PET tracer [ 18 F]MK6240. Method: Cross‐sectional data was acquired for 12 MC, 6 of whom were symptomatic, and 11 asymptomatic NC. The majority of participants (91%) were from families with PSEN1 mutations. Estimated years from symptom onset (EYO) was obtained by subtracting the age at symptom onset of a parent or sibling from the participant's age at assessment. [ 18 F]MK6240 standardized uptake value ratio (SUVR) was calculated 90‐110 minutes post‐injection using inferior cerebellar grey matter as the reference region. Statistical analyses performed included ROI‐based and voxel‐based regressions to examine the association between tau load and EYO in MC and NC. Result: ROI‐based analyses of [ 18 F]MK6240 SUVR as a function of EYO in mutation carriers revealed strong positive correlations for Braak I‐II, III‐IV, and V‐VI. None of the associations between [ 18 F]MK6240 SUVR and EYO were significant in NC. Voxel‐based analyses showed significant correlation between [ 18 F]MK6240 retention and EYO bilaterally in the entorhinal cortex and in the right posterior cingulate and precuneus in MC, while no associations survived correction for multiple comparisons in NC. Conclusion: Our results support a common pathophysiological cascade between ADAD and sporadic AD, as tau aggregation appears to follow Braak stages in both cases. Our study suggests that tau pathology appears up to 10 years before the onset of clinical symptoms. The identification of affected individuals using biomarkers early in the course of disease is crucial for better clinical outcomes. These results support the applications of disease‐modifying therapeutic interventions in the preclinical stage of AD.